AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2025
Dec 2, 2025
29821_dirs_2025-12-02_3bea8167-034d-48fc-bd4e-f6e014eab926.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2025-12-01
Reporting Person: Butcher Arthur C (EVP& Grp Pres, MedSurg & APAC)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-01 | Common Stock | M | 6952.0000 | $27.0900 | Acquired | 30552.0000 | Direct |
| 2025-12-01 | Common Stock | M | 6175.0000 | $24.5500 | Acquired | 36727.0000 | Direct |
| 2025-12-01 | Common Stock | M | 3177.0000 | $22.7100 | Acquired | 39904.0000 | Direct |
| 2025-12-01 | Common Stock | M | 1009.0000 | $17.2600 | Acquired | 40913.0000 | Direct |
| 2025-12-01 | Common Stock | S | 17313.0000 | $101.5531 | Disposed | 23600.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-01 | Stock Option (Right to Buy) | $27.0900 | M | 6952.0000 | Disposed | 2028-02-15 | Common Stock (6952.0000) | Direct |
| 2025-12-01 | Stock Option (Right to Buy) | $17.2600 | M | 1009.0000 | Disposed | 2026-02-22 | Common Stock (1009.0000) | Direct |
| 2025-12-01 | Stock Option (Right to Buy) | $24.5500 | M | 6175.0000 | Disposed | 2027-02-28 | Common Stock (6175.0000) | Direct |
| 2025-12-01 | Stock Option (Right to Buy) | $22.7100 | M | 3177.0000 | Disposed | 2026-06-01 | Common Stock (3177.0000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 13354.0000 | Indirect |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $101.11 to $101.89, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F4: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.